HC Wainwright Has Positive Forecast for TERN FY2027 Earnings

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) – Stock analysts at HC Wainwright upped their FY2027 earnings per share (EPS) estimates for Terns Pharmaceuticals in a report issued on Tuesday, December 9th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($1.56) per share for the year, up from their previous forecast of ($1.63). HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Terns Pharmaceuticals’ current full-year earnings is ($1.19) per share. HC Wainwright also issued estimates for Terns Pharmaceuticals’ FY2028 earnings at ($1.76) EPS and FY2029 earnings at ($1.98) EPS.

Terns Pharmaceuticals (NASDAQ:TERN) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.03.

Several other research analysts also recently weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Terns Pharmaceuticals in a research note on Monday. BMO Capital Markets raised their target price on Terns Pharmaceuticals from $35.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday. Mizuho lifted their target price on Terns Pharmaceuticals from $33.00 to $54.00 and gave the stock an “outperform” rating in a research report on Tuesday. Citigroup reiterated an “outperform” rating on shares of Terns Pharmaceuticals in a research note on Wednesday, November 26th. Finally, Citizens Jmp increased their price target on Terns Pharmaceuticals from $35.00 to $57.00 and gave the company a “market outperform” rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $55.56.

Terns Pharmaceuticals Stock Down 4.4%

Shares of NASDAQ:TERN opened at $45.00 on Thursday. The company has a market capitalization of $4.05 billion, a price-to-earnings ratio of -43.69 and a beta of -0.24. The company has a 50 day moving average of $19.73 and a two-hundred day moving average of $10.57. Terns Pharmaceuticals has a 52-week low of $1.87 and a 52-week high of $48.26.

Insider Activity

In related news, Director Jill M. Quigley sold 24,520 shares of the company’s stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $18.00, for a total transaction of $441,360.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 1.50% of the company’s stock.

Institutional Trading of Terns Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of TERN. Invesco Ltd. grew its position in shares of Terns Pharmaceuticals by 149.3% during the 1st quarter. Invesco Ltd. now owns 58,345 shares of the company’s stock valued at $161,000 after buying an additional 34,945 shares during the last quarter. Nuveen LLC acquired a new position in Terns Pharmaceuticals in the first quarter valued at approximately $3,880,000. Wellington Management Group LLP grew its holdings in shares of Terns Pharmaceuticals by 44.3% during the first quarter. Wellington Management Group LLP now owns 321,163 shares of the company’s stock valued at $886,000 after purchasing an additional 98,649 shares during the last quarter. EntryPoint Capital LLC grew its holdings in shares of Terns Pharmaceuticals by 21.4% during the first quarter. EntryPoint Capital LLC now owns 73,293 shares of the company’s stock valued at $202,000 after purchasing an additional 12,905 shares during the last quarter. Finally, Walleye Capital LLC raised its position in shares of Terns Pharmaceuticals by 399.8% during the 1st quarter. Walleye Capital LLC now owns 594,190 shares of the company’s stock worth $1,640,000 after purchasing an additional 475,294 shares during the period. 98.26% of the stock is owned by institutional investors and hedge funds.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.